Fosun Pharma's small molecule innovation drug Su ® into the national health insurance directory

On December 28, 2020, the State Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National List of Essential Medical Insurance, Industrial and Commercial Insurance and Maternity Insurance Drugs, which officially published the list of medicines negotiated through the National Health Insurance.
Among them, Fosun Pharma licensed the introduction of a small molecular innovation drug for the treatment of adult patients with chronic liver disease (CLD)-related plateroid reduction in selected-line diagnostic operations or surgery - Sukehin® (Malay acid Avalepopa tablets) was formally included in the national health insurance directory through negotiations.
data show that as many as 7 million people in China suffer from cirrhosis, of which up to 78% of patients with cirrhosis are accompanied by varying degrees of plate plate plate reduction.
When patients with chronic liver disease combine plateplate reduction, the risk of operation-related bleeding increases significantly, resulting in a series of clinically invasive examinations and treatments that cannot be carried out as usual, such as liver puncture biopsies, liver cancer interventional treatment, etc., making the clinical diagnosis and treatment process quite difficult.
, the need for CLD-related plateplate reduction patients to rapidly increase plate plate counts in a short period of time is particularly urgent when surgery or other invasive tests are required.
And traditional plate generation drugs and interventions in the treatment of slow, low response rate, high risk disadvantages;
clinical treatment urgently needs fast, effective, safe and convenient treatment.
The next-generation TPO-subjected astrogen Sukehin® (Malay acid avalancopopa tablets) is an oral innovation for CLD-related plate small plate plate reduction, belonging to a small molecule non-peptide class, will not be associated with endogenous Plateplate progenitin (TPO) produces sequence ogenosity and immunogenicity, no risk of antibody production, and has a plateplate effect superimposed with TPO, which makes plate count more persistent at a safe level and a low risk of potential thrombosis.
。